Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?

•Inclusion of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) of patients with leukemia and myleodysplastic syndromes (MDS) is feasible.•PROs in RCTs of patients with leukemia and MDS can provide unique information to facilitate clinical decision-making.•Disease specific PRO measures are being developed for patients with leukemia and MDS.•The number of RCTs with a PRO component in patients with leukemia and MDS is growing.